- Investing.com
Pivotal Data Ahead | Terns Pharmaceuticals approaches critical milestones for TERN-601 and TERN-701, with data releases set to potentially reshape the company's future |
Obesity Market Promise | Explore TERN-601's potential in the competitive oral GLP-1RA landscape, as Terns positions its candidate against established players and recent setbacks |
CML Treatment Innovation | Delve into TERN-701's promising efficacy in chronic myeloid leukemia, addressing unmet needs and showcasing Terns' expanding therapeutic reach |
Financial Strength | With a $315M cash position and analyst targets ranging from $14 to $34, Terns demonstrates financial stability amidst biotech market volatility |
Metrics to compare | TERN | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipTERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −63.5x | −4.7x | −0.4x | |
PEG Ratio | −8.37 | −0.18 | 0.00 | |
Price/Book | 6.1x | 6.7x | 2.6x | |
Price / LTM Sales | - | 13.3x | 3.0x | |
Upside (Analyst Target) | 0.1% | 100.0% | 51.9% | |
Fair Value Upside | Unlock | 5.5% | 9.1% | Unlock |